Places
Location unknown
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune ...
Mar 25, 2024 · Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC).
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases.
People also search for
People also ask
Who is the founder of Landos Biopharma?
What does RedHill Biopharma do?
Mar 25, 2024 · Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC).
In 1915, Salvatore Lando left his home in Ucria, Sicily to travel to America to give his wife and three sons a better life, and arrived in Massachusetts.